NCT01209325 · OUTCOME
Geometric Mean Titers for HPV 16
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males · Source last updated 2020-08-11
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- GEOMETRIC_MEAN
- Unit
- mMU/mL
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Baseline through 24 months
What was measured
Geometric mean concentration of antibodies for HPV 16 at each visit
Analysis population: Eligible participants who received at least one vaccination with evaluable serum assessments.
Groups in this outcome
HPV 16 Sero-negative at Baseline
Sero-negative for HPV 16 at baseline.
HPV 16 Sero-positive at Baseline
Sero-positive for HPV 16 at baseline
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
| Group | Source count |
|---|
| HPV 16 Sero-negative at Baseline | 92 |
|---|
| HPV 16 Sero-positive at Baseline | 51 |
|---|
Reported measurements
Baseline
Analysis denominator · Participants
| Group | Source count |
|---|
| HPV 16 Sero-negative at Baseline | 92 |
|---|
| HPV 16 Sero-positive at Baseline | 51 |
|---|
Values in mMU/mL · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| HPV 16 Sero-negative at Baseline | 0 | Not reported | 0 | 0 | Not reported |
|---|
| HPV 16 Sero-positive at Baseline | 66.6 | Not reported | 46.7 | 95.1 | Not reported |
|---|
Month 7
Analysis denominator · Participants
| Group | Source count |
|---|
| HPV 16 Sero-negative at Baseline | 82 |
|---|
| HPV 16 Sero-positive at Baseline | 45 |
|---|
Values in mMU/mL · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| HPV 16 Sero-negative at Baseline | 1535.6 | Not reported | 1272.5 | 1853.1 | Not reported |
|---|
| HPV 16 Sero-positive at Baseline | 2947.8 | Not reported | 2249.0 | 3863.6 | Not reported |
|---|
Month 12
Analysis denominator · Participants
| Group | Source count |
|---|
| HPV 16 Sero-negative at Baseline | 76 |
|---|
| HPV 16 Sero-positive at Baseline | 42 |
|---|
Values in mMU/mL · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| HPV 16 Sero-negative at Baseline | 451.6 | Not reported | 352.5 | 578.5 | Not reported |
|---|
| HPV 16 Sero-positive at Baseline | 1436.6 | Not reported | 1095.2 | 1884.6 | Not reported |
|---|
Month 18
Analysis denominator · Participants
| Group | Source count |
|---|
| HPV 16 Sero-negative at Baseline | 73 |
|---|
| HPV 16 Sero-positive at Baseline | 38 |
|---|
Values in mMU/mL · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| HPV 16 Sero-negative at Baseline | 309.5 | Not reported | 237.6 | 403.1 | Not reported |
|---|
| HPV 16 Sero-positive at Baseline | 1242.9 | Not reported | 892.2 | 1731.5 | Not reported |
|---|
Month 24
Analysis denominator · Participants
| Group | Source count |
|---|
| HPV 16 Sero-negative at Baseline | 67 |
|---|
| HPV 16 Sero-positive at Baseline | 37 |
|---|
Values in mMU/mL · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| HPV 16 Sero-negative at Baseline | 272.4 | Not reported | 195.5 | 379.6 | Not reported |
|---|
| HPV 16 Sero-positive at Baseline | 1079.5 | Not reported | 771.8 | 1510.0 | Not reported |
|---|
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0
- upper Limit
- 0
- value
- 0
- group Id
- OG001
- lower Limit
- 46.7
- upper Limit
- 95.1
- value
- 66.6
- denoms
- counts
- group Id
- OG000
- value
- 92
- group Id
- OG001
- value
- 51
- units
- Participants
- title
- Baseline
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1272.5
- upper Limit
- 1853.1
- value
- 1535.6
- group Id
- OG001
- lower Limit
- 2249.0
- upper Limit
- 3863.6
- value
- 2947.8
- denoms
- counts
- group Id
- OG000
- value
- 82
- group Id
- OG001
- value
- 45
- units
- Participants
- title
- Month 7
- categories
- measurements
- group Id
- OG000
- lower Limit
- 352.5
- upper Limit
- 578.5
- value
- 451.6
- group Id
- OG001
- lower Limit
- 1095.2
- upper Limit
- 1884.6
- value
- 1436.6
- denoms
- counts
- group Id
- OG000
- value
- 76
- group Id
- OG001
- value
- 42
- units
- Participants
- title
- Month 12
- categories
- measurements
- group Id
- OG000
- lower Limit
- 237.6
- upper Limit
- 403.1
- value
- 309.5
- group Id
- OG001
- lower Limit
- 892.2
- upper Limit
- 1731.5
- value
- 1242.9
- denoms
- counts
- group Id
- OG000
- value
- 73
- group Id
- OG001
- value
- 38
- units
- Participants
- title
- Month 18
- categories
- measurements
- group Id
- OG000
- lower Limit
- 195.5
- upper Limit
- 379.6
- value
- 272.4
- group Id
- OG001
- lower Limit
- 771.8
- upper Limit
- 1510.0
- value
- 1079.5
- denoms
- counts
- group Id
- OG000
- value
- 67
- group Id
- OG001
- value
- 37
- units
- Participants
- title
- Month 24
- denoms
- counts
- group Id
- OG000
- value
- 92
- group Id
- OG001
- value
- 51
- units
- Participants
- description
- Geometric mean concentration of antibodies for HPV 16 at each visit
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Sero-negative for HPV 16 at baseline.
- id
- OG000
- title
- HPV 16 Sero-negative at Baseline
- description
- Sero-positive for HPV 16 at baseline
- id
- OG001
- title
- HPV 16 Sero-positive at Baseline
- param Type
- GEOMETRIC_MEAN
- population Description
- Eligible participants who received at least one vaccination with evaluable serum assessments.
- reporting Status
- POSTED
- time Frame
- Baseline through 24 months
- title
- Geometric Mean Titers for HPV 16
- type
- SECONDARY
- unit Of Measure
- mMU/mL
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle